In order to explore the effect of Modified Jiegeng Yuanshen Decoction（桔梗元参汤加减）in the treatment of allergic rhinitis（AR）mediated by advanced glycation end product（AGE）-receptor for advanced glycation end product（RAGE）signaling pathway.

A total of 260 patients with AR treated in the hospital from January 2022 to June 2023 were selected and divided into a control group（130 cases）and an observation group（130 cases）by random number table method. The control group was given loratadine，and the observation group was treated with Modified Jiegeng Yuanshen Decoction of the hospital. The total effective rate，clinical symptoms，expression levels of AGE and RAGE proteins，inflammatory indicators［nuclear factor kappa-B（NF-κB），interleukin-6（IL-6），reactive oxygen species（ROS）］and adverse reactions were compared between the two groups.

Compared with that of the control group，the total effective rate of the observation group was significantly higher（P<0.05），and the clinical symptom scores were significantly decreased（P<0.05），the expression levels of AGEand RAGEproteins and the levels of NF-κB，IL-6 and ROSwere significantly decreased（P<0.05）. Mild adverse reactions such as dizziness，fatigue and gastrointestinal discomfort occurred in both groups. The incidence of adverse reactions in the observation group was slightly lower than that in the control group，but there was no significant difference（P>0.05）.

Modified Jiegeng Yuanshen Decoction can reduce the degree of inflammatory response in patients with AR by inhibiting AGE-RAGE/NF-κB/IL-6 and AGE-RAGE/ROSsignaling pathways，thereby improving the treatment efficiency and relieving clinical symptoms.